NASDAQ: FDMT4d Molecular Therapeutics Inc Stock
$4.22-0.14 (-3.21%)
Updated Jul 18, 2025
FDMT Price
$4.22
Fair Value Price
$2.31
Market Cap
$195.49M
52 Week Low
$2.24
52 Week High
$19.69
P/E
-1.33x
P/B
0.42x
P/S
7,828.41x
PEG
N/A
Dividend Yield
N/A
Revenue
$23.00k
Earnings
-$176.44M
Gross Margin
100%
Operating Margin
-767,126.09%
Profit Margin
-767,126.1%
Debt to Equity
0.1
Operating Cash Flow
-$153M
Beta
1.33
Next Earnings
Aug 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
FDMT Overview
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy that uses adeno-associated virus vectors to develop product candidates in three therapeutic areas: ophthalmology, cardiology, and pulmonology. 4D Molecular Therapeutics has research and collaboration arrangements with uniQure, CRF, Roche, and CFF. The company was founded in 2013 and is headquartered in Emeryville, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine FDMT's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
FDMT
Ranked#371 of 476
Ranked#371 of 476
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.40 | A | |
| $8.63 | A | |
| $67.86 | A |
Be the first to know about important FDMT news, forecast changes, insider trades & much more!
FDMT News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how FDMT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
FDMT ($4.22) is overvalued by 82.85% relative to our estimate of its Fair Value price of $2.31 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
FDMT ($4.22) is not significantly undervalued (82.85%) relative to our estimate of its Fair Value price of $2.31 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
FDMT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more FDMT due diligence checks available for Premium users.
Valuation
FDMT fair value
Fair Value of FDMT stock based on Discounted Cash Flow (DCF)
Price
$4.22
Fair Value
$2.31
Overvalued by
82.85%
FDMT ($4.22) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
FDMT ($4.22) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
FDMT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
FDMT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.33x
Industry
-179.53x
Market
31.42x
FDMT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.42x
Industry
4.56x
FDMT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
FDMT's financial health
Profit margin
Revenue
$14.0k
Net Income
-$48.0M
Profit Margin
-342,657.1%
FDMT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
FDMT's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$515.7M
Liabilities
$46.0M
Debt to equity
0.1
FDMT's short-term assets ($332.57M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
FDMT's short-term assets ($332.57M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
FDMT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$47.8M
Investing
$31.9M
Financing
$0.0
FDMT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
FDMT vs Biotech Stocks
4d Molecular Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.